Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Education » Book Chapters » Focus on Leukemia Research Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
_Cancer Research Journal - This journal ceased publication after 4#4 (2010). Back Issues are available.
$195.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Cellular Immunotherapy of Leukemia (pp. 113-138)
Tell A Friend
 
Tell someone you know about this product.
Cellular Immunotherapy of Leukemia (pp. 113-138) $25.00
Authors:  Yasukawa, Masaki (Ehime University School of Medicine, Ehime, Japan)
Abstract:
Recent findings from basic researches and clinical observations have revealed that the effectiveness of chemotherapy against leukemia is limited and the immunosurveillance system is important to achieve cure of hematological malignancies. Cytotoxic T lymphocytes (CTL) undoubtedly play an important role in resistance to cancers, including various types of hematopoietic malignancy. To develop effective cellular immunotherapy of hematopoietic malignancy, the tumor-associated antigens that are recognized by CTL must be identified. Recently, various leukaemia-associated antigens that are recognized by CTL in the context of HLA class I molecules have been identified. These include fusion gene products such as BCR-ABL and ETV6-AML1, proteinase 3, Wilms' tumour gene product (WT1), human telomerase reverse transcriptase, cyclophilin B, and PRAME. In addition, various target antigens associated with other hematopoietic malignancies have been also identified. On the basis of these findings, various clinical trials of immunotherapy against hematological malignancies, including peptide vaccination, DC therapy, adoptive transfer of CTL have been ongoing. Here, the current status and future feasibility of cellular immunotherapy against hematological malignancies are discussed. 


Available Options:
Version:
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Cellular Immunotherapy of Leukemia (pp. 113-138)